4 active not recruiting, 2 recruiting, 1 terminated. 4 Phase 2, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow Telitacicept 160mg: new trials by email Literature Review of Telitacicept 160mg trials Research Report on Telitacicept 160mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis Telitacicept 160mg, Standard therapy - Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis | Phase 2 | Recruiting | Peking University People's Hospital | 420 | 2026-09-01 | 2026-09-01 |
| Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease Telitacicept 160mg, Conventional treatment - Sjögren's Disease, Interstitial Lung Disease | Recruiting | Peking University People's Hospital | 60 | 2026-05-01 | 2026-09-28 | |
| Telitacicept for PGNMID: A Single-Arm Study Telitacicept 160mg - Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits | Phase 2 | Active not recruiting | Peking University First Hospital | 10 | 2025-07-12 | 2025-08-08 |
| Immune Cell Subsets in SLE Patients Treated with Telitacicept Telitacicept 160mg - Systemic Lupus Erythematosus (SLE) | Phase 4 | Active not recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2024-10-11 | 2024-11-07 |
| The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) Telitacicept 160mg, Prednisone (and methylprednisolone), Cyclophosphamide - Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) | Phase 1 / Phase 2 | Active not recruiting | Renmin Hospital of Wuhan University | 15 | 2024-10-10 | 2024-10-24 |
| To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy Telitacicept 160mg, Corticosteroid, ACE Inhibitor or Angiotensin receptor antagonist - IgA Nephropathy (IgAN) | Phase 3 | Active not recruiting | The Affiliated Hospital of Xuzhou Medical University | 150 | 2024-08-01 | 2025-08-01 |
| A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy Telitacicept 160mg, Telitacicept 240mg, Placebo - IgA Nephropathy | Phase 2 | Terminated | RemeGen Co., Ltd. | 15 | 2021-11-04 | 2023-12-06 |
Glomerulonephritis, IGA (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Arthritis, Rheumatoid (1) · Lung Diseases, Interstitial (1) · Lupus Erythematosus, Systemic (1) · Sjogren's Syndrome (1)
Peking University People's Hospital (2) · Peking University First Hospital (1) · RemeGen Co., Ltd. (1) · Renmin Hospital of Wuhan University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · The Affiliated Hospital of Xuzhou Medical University (1)
China (6) · United States (1)
Fude Zhou, MD (1) · Yuan Jia (1)